Q&A: How the Chinese Private Sector Can Help Develop Pharmaceutical Production Capacity in Africa

 In Advertising, analysis, Q&A

The COVID-19 pandemic has brought into sharp relief the highly unsustainable fact that African countries together import over 70% of all pharmaceutical and medical products. Yet, 34 out of 55 African countries have some level of pharmaceutical production, with countries offering an array of incentives to encourage pharmaceutical investment. These opportunities have been available and well known to investors from Europe and other OECD countries for many years, and many have been grabbed by Indian manufacturers. But what about Chinese investors? What is their perspective of the African market? Can they play a role in rectifying this situation, including for COVID-19 recovery?

To gain insight into this question, Development Reimagined spoke to Li Wensheng, CEO of Humanwell Healthcare Group Africa, a private Chinese pharmaceutical company already operating in Mali and Ethiopia.

DEVELOPMENT REIMAGINED: Mr. Li, thank you for speaking with us today. To start, could you give us a brief overview of your experience in Africa’s pharmaceutical sector?

LI WENSHENGFirst up, as reported by Goldstein Market Intelligence, in 2017 the value of the continent’s pharmaceutical industry was $28.56 billion – a substantial increase from its $5.5 billion value just a decade earlier. Despite this, the market remains underdeveloped and highly fragmented. The entire continent only has 375 pharmaceutical companies, with a significant number concentrated in North Africa. When accounting for just Sub-Saharan Africa, the pharmaceutical market shrinks to only $14 billion. This is further dwarfed when compared to other countries with similar-sized populations as the continents. China, for instance, has around 5,000 drug manufacturers and a market value of $120 billion, whilst India has 10,500 drug manufacturers and a $19 billion market value. There is no doubt in my experience that the sector is underdeveloped here in Africa.

And the implications of this underdevelopment have been illuminated by the pandemic. Only 3 African countries plan to produce vaccines (Morocco, Egypt and South Africa), with most countries relying on imports which place additional fiscal pressure on governments. The Africa Centre of Disease Control (Africa CDC) has estimated the cost of vaccinating 60% of the population will be between $7-$10 billion. Supporting local manufacturing and building capacity simply cannot wait, nor can the people waiting for lifesaving or essential drugs.

The idea of new partnerships between China and Africa to support the sector’s growth has been around for a few years now. For example, pharmaceutical investment was included in the 2015 Forum on China-Africa Cooperation Beijing Action Plan. Additionally, just before the pandemic outbreak, the China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) hosted the Convention on Pharmaceuticals China, which facilitated talks between Chinese pharmaceutical investors with African delegates.

DEVELOPMENT REIMAGINED: Why is China-Africa pharmaceutical investment important? Isn’t one of the issues that China is exporting to Africa too much?

LI: Far from stopping the development of the sector, there are actually several ways Chinese investors can support the growth of Africa’s pharmaceutical sector. For instance, Chinese investment can combat the counterfeit medicine trade, which is particularly rife in Africa, with 42% of all counterfeit medicines reported to the WHO from 2013 to 2017[MOU1]  coming from the continent. This is extremely dangerous and has led to avoidable deaths and extra costs. One analysis estimated that fake or poor quality antimalarials in Africa had caused around 116,000 further deaths, creating additional fiscal pressure of $38.5 million to treat those who required care. But as investment in the pharmaceutical industry grows, and access to high-quality medicines expands, the market for fake medical products will shrink.

Another way we can help as investors is to build capacity through skills transfer and improvement in local management techniques. The pharmaceutical industry requires standardization with strict regulations, with highly technical practices. Chinese enterprises, through direct investment and joint ventures, can provide advanced management techniques and share knowledge we have developed from our own pharmaceutical development experience. Transferring this knowledge to local workers and managers will support the industry’s long-term development.

Finally, and most importantly, we can increase the accessibility of lifesaving and everyday pharmaceutical supplies. For example, in the first few months of the pandemic, between April and June 2020, the continents’ total exports of COVID-19 medical supplies equated to only $422 million, with South Africa accounting for 92% of this. Comparatively, between January and June 2020, total imports of COVID-19 medical supplies equated to roughly $2.7 billion, with three main import sources being China (26%), India (16%), and the US (11%).

This imbalance, this dependency is unsustainable. But when manufacturing is localized, the factory can produce supplies most suited to the local market needs and enables governments to better address health concerns through this enhanced capacity. Transaction costs will also decline through the reduction in import and logistic costs, which in turn decreases the price of medicine, making them more affordable and accessible.

DEVELOPMENT REIMAGINED: Thank you for those important insights. Now, you have invested yourself into the African pharmaceutical sector, what challenges did you meet when doing so?

LI: This is an important question. The biggest challenge was certainly the low levels of infrastructure. The African Development Bank estimates there is a total financing gap of US$52 – $92 billion per year. Inadequate infrastructure has direct implications on the supply chain. For instance, we still rely on some imported products to manufacture our medicines, but the fragmented supply chain makes reduces efficiency and increases our costs.

Image via Humanwell Healthcare.

We also witnessed the realities of poor infrastructure in the pharmaceutical sector with the COVID-19 vaccines, as many countries did not possess appropriate cold storage facilities for vaccine transportation and storage.

A second challenge we have met is a mismatch between donations and local procurement. The Chinese government and international organizations donate – for free – vast amounts of medicines to Africa every year. However, these products are from China and Western countries, whereas procurement from local manufacturers would be more efficient in terms of time, logistics, and cost, plus it would support the domestic manufacturing industry. It is important that in the future this system works better to respond to public health threats in a timely and efficient manner.

Finally, hiring local staff has been challenging, as training costs can be substantial, especially if there are significant gaps in knowledge or skillset. To help build capacity, further support from both the African and Chinese governments is needed through mechanisms such as subsidized training programs. Within this, communication with Chinese pharmaceutical actors is essential, as we have the equipment and facilities for this training.

DEVELOPMENT REIMAGINED: Right – it’s clear that the issues go beyond China-Africa – even to international procurement systems and financing. So, does that mean the African and Chinese government’s role is limited? Can they do anything to encourage more private sector investment in pharmaceuticals, given these challenges?

LI: Yes, the challenges are big, but I have two specific ideas for what can be done.

As I mentioned, many international organizations like the WHO donate medications similar to what we produce, such as anti-malaria or anti-tuberculosis drugs. A monitoring system between the host country government, the Chinese government, and local manufacturers would allow us to establish quarterly plans for donations to ensure that medicine remains high-quality, effective, and in good supply.

Another tool would be to establish robust frameworks on intra-regional pharmaceutical trade. Our products supply Western Africa, including Mali, Senegal, Cote d’Ivoire, which are all members of the Economic Community of West African States (ECOWAS). Technically no tariff should be paid when importing locally produced product from a member country. However, our company experiences issues in getting the required documents when exporting our medicines to other ECOWAS countries – which not only slows down our export process but prolongs the time that countries receive drugs.

DEVELOPMENT REIMAGINED: These are very important suggestions, and we agree – we hope they can be put into action. Now, post-COVID, do you think there will be better or worse opportunities for the continent’s domestic pharmaceutical sector?

LI: African governments have done particularly well in managing the virus. But most still face limited capacity in testing and vaccinating. As reported in March, African countries had received under 2% of the vaccines they ordered – these long delays are postponing economic recovery.

What COVID has revealed is the vital need to expand the variety of products manufactured. Masks, alcohol, and sterilization products, alongside household drugs, will help prepare African countries to respond to disease threats. For instance, the costs of PPE increased massively during COVID – with one report calculating a 6,163% increase for 3M N95 masks (jumping from $0.11 to $6.75 per mask!). There is definitely an opportunity here for Chinese investors to support the local manufacturing of these essentials, especially as China has a firm advantage in producing these products.

But Chinese investors must research the opportunities out there. For instance, the 2018 report commissioned by UNAIDS and CCCMHPIE surveyed 21 African countries – this is really useful. That report reveals that 90% of countries provided import incentives for active pharmaceutical ingredients, excipients, and machinery for production, 80% provided tax incentives, and 60% provided free allocation of land or planned a pharmaceutical industrial park. Such incentives significantly reduce transaction costs for investors.

Further, opportunities in the pharmaceutical industry’s supply chain remain largely untapped. There is a big gap with sourcing raw materials, packaging and labeling, and transportation, which Chinese companies should also seek to invest in. This would support employment creation within Africa as the supply chain becomes more established. A complete supply chain therefore can create a win-win situation for both African countries and Chinese counterparts.


This article was first published on The China Africa Project on April 23rd, 2021.

Recommended Posts

Leave a Comment

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt


Research Analyst

Edmond is a research analyst who is passionate about sustainable development, innovation, and the environment. Passionate about climate financing, he firmly believe there is a more reliable system to promote equality, growth, and welfare in societies without affecting the ecosystem. Through his skills, knowledge and experienced gained over 7 years, he wants to make an impact in the world of development. Edmond holds a Master’s Degree in Public Policy from Korea Development Institute and a BA Degree (Honors) in Business from University of Derby.


    Founder and CEO

Hannah Ryder is the Founder & CEO of Development Reimagined. A former diplomat and economist with 20 years of experience, named one of 100 most influential Africans in 2021, she is also Senior Associate for the Africa Program of the Center for Strategic International Studies (CSIS), sits on the Board of the Environmental Defence Fund, and is a member of UAE's International Advisory Council on the New Economy. Prior to her role at DR, Ms Ryder led the United Nations Development Programme (UNDP)’s work with China to help it scale up and improve its cooperation with other developing countries, including in Africa. She has also played various advisory roles for the UN and OECD and co-authored the seminal Stern Review of the Economics of Climate Change in 2006.


Deputy Director

Leah Lynch is Deputy Director of Development Reimagined (DR), and head of the China office. Leah has over 10 years of experience in development and has lived in China for over 8 years. Leah has also travelled extensively around Asia and Africa for research. Leah supports the strategic direction of the team across China, with a mission to deliver high quality research on sustainable development and poverty reduction. Leah is also Chair of the Sustainability Forum at the British Chamber of Commerce in China, providing direction on sustainability initiatives for British and Chinese business. Leah has also consulted on various evaluations on UK aid (ICAI) and is a specialist on development cooperation from the UK and China. Leah has also consulted on various UN projects, including providing support to the UN China team during the COVID-19 Pandemic. Prior to DR, Leah was at the United Nations Development Programme (UNDP) China, supporting the UN’s portfolio on communication strategies, China’s South- South Cooperation and the Belt and Road Initiative (BRI). Before UNDP, Leah lived and worked in Kenya developing sustainable water policies for the Kenyan government.


China-Africa Policy Analyst

Yike Fu is a Policy Analyst and has been responsible for leading numerous areas of work, including on debt analysis in Africa and beyond, and China-Africa trade and investment logistics and analysis. She is the co-author of “African Debt Guide”, in which she challenged the narrative that Africa is in the midst of a new debt crisis by analysing data back to the 1970s and adopting new metrics to present the real story behind the data. She also developed a benchmark to compare the financial distribution of development partners such as the UK, US, Japan, France and China in Africa. Prior to her role at DR she worked at the International Finance Corporation and African Union Representational Mission to the US. She holds a Masters in International Affairs from George Washington University.


Research Analyst

Judith is a Research and Policy Analyst, where she specialises in Africa-China relations, international development, and diplomacy. During her time at Development Reimagined, Judith has co-authored several articles published in The Diplomat on debt and China-Barbados relations and was quoted by China Daily in a piece on Women Rights in China. Previously, Judith worked as a research analyst for an Advocate and Commissioner and Oats office in Kenya.


Policy Analyst

Ovigwe specialises in geopolitics with particular reference to Africa in a changing Global Order. He is adept at critically analysing the politics of contemporary development processes and providing insight into the geopolitical interests that influence them. His work includes research, publications, tailored briefings and advising on global and regional trends, and issues at the nexus of geopolitics and development. Ovigwe appears frequently in media around the world such as Al Jazeera, TRT World, SABC, CGTN, BBC Radio, and other platforms.


Policy Analyst

Jing leads China-African health and agriculture cooperation research at Development Reimagined, having managed our FOCAC Policy Analysis and Advocacy project. She is also the co-author of “China-Africa Health Cooperation under FOCAC Umbrella”, in which she analysed China’s commitments around health cooperation since the first FOCAC summit and deepdived into four African countries’ health overview, challenges and cooperation with China as cases studies. Before DR, Jing worked at GIZ Cambodia on M&E of a disability advocacy project. She also worked as a translator with Chinese medical team in Benin.


Trade Policy Analyst

Patrick is an International Trade Policy and Trade Law Expert with over 5 years of experience. His expertise includes trade law, trade policy analysis and regional integration. He is currently engaged with Development Reimagined as a Senior Trade Analyst and was the lead author of Development Reimagined's recent Report on Africa-China Relations titled "From China-Africa to Africa- China: A Blue Print for a Green and Inclusive Continent-Wide Strategy Towards China." and “Reimaging FOCAC Going Forward.” Patrick has previously consulted for the East African Community, UNECA and for the Kenya Ministry of Trade.


Senior Policy Analyst 

Rosemary is our Senior Policy Analyst. She is a skilled policy analyst and has previously worked as a UK civil servant. She is studying Human Rights at Birkbeck, University of London with a research focus on international law in the context of health crises such as the COVID-19 pandemic.


Project Manager and Africa-China Communication Assistant

Jade is a Project Manager for Development Reimagined’s flagship project Africa Unconstrained, which focuses on financing needs and debt vulnerabilities of African countries. Her research focuses on China-Africa development finance alongside debt vulnerabilities, infrastructure needs and South-South cooperation. She has worked with a breadth of stakeholders from China, Africa and the wider international community, including governments, private sector, NGOs and civil society. Her writing has appeared in a number of publications, including The Africa Report, The China-Africa Project, The Diplomat and more. Jade holds a Master’s in China and Globalisation studies from King’s College London.


Programme Manager

Rosie is the Project Manager of Africa Reimagined (AR) at Development Reimagined (DR) where she supports high-end African brands with entering the Chinese market by operating services such as trademark protection, Chinese market research, Chinese partnership building, and Africa to China logistical support and import/export services. Rosie has worked with DR for over two years now with proven success in helping high-end African brands navigate the Chinese market. She is extremely passionate about her work because more African brands selling in the Chinese marketplace means African countries can export MORE value-added goods, create MORE jobs and foster MORE innovation in African countries.

Rosie is also alumni of the School of International Studies at Peking University in Beijing where she is also an editor at the Peking Africa Think Tank. PATT is led by a diverse group of scholars who specialise in African Studies within the context of Sino-Africa relations.



Lauren has lived in six countries from the Americas to Europe and Asia and speaks both French and Spanish proficiently. At Development Reimagined, Lauren’s research focuses on climate action both in the Asia-Pacific and in Africa, and how countries are using tools such as SDGs and Covid-19 action to build a more climate-resilient future. She holds a Masters in International Relations from Leiden University.



Etsehiwot holds a Masters’s degree in Development Studies from the London School of Economics. She has diverse experience in humanitarian and development issues by working in both multilateral organizations and international non-governmental organizations. Etsehiwot is currently a consultant focusing on the SDGs and development finance.


Economist Consultant

Dibekulu is an economist by training. He holds an MSc in International Development Studies from Palacky University Olomouc, an MSc in Development Economics from the University of Clermont Auvergne, and an MSc in Economics, Finance, and International Integration from the University of Pavia. At Development Reimagined, he works as an Economist consultant. He has strong data analysis skills, with research interests centring around development finance, impact assessment, food security, and agricultural insurance.


Project Manager

Osaru is a health professional with an MSc in Health Systems Policy and an interest in women’s health and population management. At Development Reimagined, she applies her health sector experience to global health research and collating locally applicable development insights from China.


Research Analyst

Ferdinando’s research at Development Reimagined is centred on South-South Cooperation dynamics, specifically on the analysis of Chinese investment and debt flows in Africa and their linkages to African industrialisation. He is currently a Yenching Scholar at Peking University, after having graduated from the University of Cambridge with an MPhil in Development Studies.


Research Analyst

David is a Research and data analyst at Development Reimagined. His scholarly focus is mostly on interdisciplinary research in demographic economics and development with interests in migration, economic development and policy, education, health and subjective well-being. He is currently a PhD scholar at Nelson Mandela University from which he also holds B.com Economics and Statistics and M.com respectively.


Research Analyst Kenya

Ivory is a Kenyan lawyer with experience in policy research and analysis. She also supports the communications team at DR. Ivory speaks English, Swahili and French.


Research And Data Analyst China 

Joy Ene is a Research and Data Analyst at DR. Joy is passionate about African/global development, poverty eradication and trade policies between underdeveloped and developing countries. She is also a fourth-year student of International Economics and Trade at the  Liaoning University, Shenyang, China. She serves as the President of the Student Union, Liaoning University, International Students chapter.


Research Analyst 

Chensi Li is a research analyst. She has previously worked for local NGOs in Nigeria and Cameroon and think-tanks in China.  Her research areas include Sino-African relations, African foreign affairs, public diplomacy, state-building and national governance.

Yixin Yu

Research Analyst 

Yixin is a Junior Research Analyst and her focus areas is on public-private partnership and entrepreneurship. She has over three years of working experience in both private and public sectors in Ethiopia. She was the China Liaison Officer for project ‘Partnership for Investment and Growth in Africa’ at International Trade Centre, where she accumulated rich experience in investment and trade promotion


Founder and CEO

Hannah Ryder is the Founder & CEO of Development Reimagined. A former diplomat and economist with 20 years of experience, named one of 100 most influential Africans in 2021, she is also Senior Associate for the Africa Program of the Center for Strategic International Studies (CSIS), sits on the Board of the Environmental Defence Fund, and is a member of UAE's International Advisory Council on the New Economy. Prior to her role at DR, Ms Ryder led the United Nations Development Programme (UNDP)’s work with China to help it scale up and improve its cooperation with other developing countries, including in Africa. She has also played various advisory roles for the UN and OECD and co-authored the seminal Stern Review of the Economics of Climate Change in 2006.